Introduction

Endoscopic management of high-grade dysplasia (HGD) of the esophagus, an alternative to esophagectomy, was first introduced in 1992 and has been recognized as standard of care since 2009 (1,2). Prior to that, esophagectomy was the standard of care due to association between malignancy and HGD among patients with Barrett’s esophagus (BE). Less than 1% per year of patients with BE will develop HGD but up to 40% of these patients will go on to develop invasive adenocarcinoma (3-5). Most patients with HGD are now manageable with a combination of endoscopic options; including endoscopic mucosal resection (EMR), endoscopic submucosal dissection (ESD), radiofrequency ablation (RFA), argon plasma coagulation (APC) and cryoablation (6-10). These treatments have become the preferred therapy for most patients with HGD or superficial esophageal cancer because they offer esophageal preservation, similar long-term survival, and significantly fewer complications compared with esophagectomy (11).

While endoscopic therapy is preferred over surgical therapy for HGD, guidelines for selecting which patient would benefit from surgical management are absent (12). Many surgeons believe that esophagectomy is more appropriate in individuals with poor esophageal body function, severe and/or uncontrollable reflux symptoms, dysphagia, or frequent aspiration (13). This systematic review aims to examine current literature to define the role of surgery in the treatment of HGD.

Data sources

English-language studies in persons older than 18 were
identified by searching the MEDLINE database from January 2010 to December 2018. In 1992 EMR with fitted cap was first published by Dr. Inoue, however, endoscopic treatment of HGD was not an acceptable standard of care until 2009 (1,2). Therefore, only studies published after 2009 were considered.

Study selection

Three independent assessors reviewed all papers for inclusion. Key words used to identify articles included “esophageal high-grade dysplasia” and “surgery”. All identified articles were systematically assessed using the inclusion and exclusion criteria. The reference lists of articles matching inclusion criteria were then reviewed for further identification of potentially relevant studies. All retrieved citations were reviewed to identify all experimental, cohort, or case-control studies that compared treatment options and outcomes for patients with HGD.

Selection criteria

Studies in which patients had a diagnosis of HGD or Barrett’s dysplasia were included for review. Case reports and review articles were excluded. Only retrospective or prospective studies were included. After review of full text, additional studies were excluded if surgical intervention or referral to surgery was not evaluated or mentioned.

Data extraction

Article text, figures, and tables were reviewed. Three investigators (SG Worrell, KE Bingmer, A Ofshteyn) reviewed studies selected through exclusion and inclusion criteria. Discrepancies between the two reviewers were resolved by discussion until consensus achieved. There have been 1,104 papers published since 1992 and 518 since 2010. All 518 titles were reviewed and excluded using the selection criteria above. This including exclusion of case reports, basic science papers, and review articles. After this, there were 156 remaining papers. All abstracts of the 156 manuscripts were reviewed, 35 papers were selected to be individually reviewed. Final selection identified 20 papers (Figure 1) for inclusion.

Data synthesis

Among 35 studies that were fully reviewed, 20 papers mentioned both endoscopic therapy and surgery and were included in this review. Among the 20 studies, there were no randomized controlled trials, but in aggregate these studies included at least 781 patients with HGD alone.
and over 1,566 patients with either HGD or intramucosal adenocarcinoma (IMC).

There were only two studies which directly compared the outcomes of endoscopic and surgical treatment (Table 1) (14,15). Both of these studies were retrospective and included both HGD and IMC. Endoscopic eradication was achieved in 45–70% with a recurrence rate of 6–20% (14,15).

The remaining 18 studies were non-comparative, case-control studies. The indication for surgery was progression to cancer, failure to clear disease, or recurrence of HGD or IMC during surveillance after HGD had been cleared with an overall referral to surgery rate of 0 to 24%. Of these 18 articles, 14 discussed outcomes of HGD with varying intervention. The other four articles addressed cost effectiveness and surgical outcomes alone and are discussed in the appropriate sub-sections. Specific outcomes of the 14 studies are shown in Table 2, including surgery rate, clinical outcomes, and recurrence rate. These studies demonstrate some of the adverse outcomes associated with endoscopic treatment. There was a post-treatment stricture rate of 2% to 26%, which was higher among patients treated with the ESD technique. There was a recurrence rate of dysplasia of 3% to 21%, with the majority of recurrences occurring within the first two years following initial treatment. Overall 5-year survival rate was between 77% to 91% for all treatments. A proposed treatment algorithm with consideration of special topics, addressed below, is shown in Figure 2.

Pathologist expertise

A potentially overlooked contraindication to endoscopic treatment of HGD and IMC is the absence of a reliable pathologist who can correctly interpret the endoscopic specimens as well as an endoscopist who can provide reliable specimens. In the paper by Small and colleagues, aiming to compare eradication of HGD and IMC with EMR +/- ablation, they found that 29% (54/189) of patients initially referred for therapy of BE with HGD had esophageal cancer. The majority had IMC, but 2% (4/189) had more invasive pathology, requiring esophagectomy (9). Furthermore, in another study of 67 patients referred with biopsies consistent with HGD, endoscopic resection (ER) specimens showed cancer in 13/67 (19%) with submucosal adenocarcinoma in 3/67 (7%) (21). The inter-observer variability is also acknowledged by the American College of Gastroenterology (ACG) guidelines who recommend any diagnosis of dysplasia of any grade should be reviewed by two pathologists, at least one with specialized expertise in gastrointestinal (GI) pathology (25).

Risk of endoscopic therapy failure

Patients with a large hiatal hernia and longer segment of BE are less likely to have complete eradication of dysplasia with RFA (8). In a cohort of 121 patients with dysplasia, 91 patients (75%) had complete eradication with a single treatment of RFA (8). There was recurrence of dysplasia in three patients (3%, 3/91). Among the 121 patients, 4
Table 2 Clinical outcomes for all interventions for the treatment of HGD

<table>
<thead>
<tr>
<th>Therapy</th>
<th>N</th>
<th>Referred for surgery</th>
<th>BE length [IQR] in cm</th>
<th>Median number of treatments [IQR]</th>
<th>Complications</th>
<th>Progression to cancer</th>
<th>Stricture</th>
<th>Persistent dysplasia</th>
<th>Recurrence of HGD or IMC</th>
<th>Median follow-up (range or IQR) in months</th>
<th>5-year survival</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Cryotherapy</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ramay (7)</td>
<td>50 HGD and IMC</td>
<td>1/50 (2%)</td>
<td>3.5 [2–5]</td>
<td>3 [2–5]</td>
<td>NR</td>
<td>2/50 (4.0%)</td>
<td>NR</td>
<td>4/50 (8.0%)</td>
<td>8/49 (16%) at median 8 months</td>
<td>64.6 NR</td>
<td></td>
</tr>
<tr>
<td>Halsey (16)</td>
<td>68 HGD</td>
<td>NR</td>
<td>3 [2–5]</td>
<td>NR</td>
<td>NR</td>
<td>1/68 (1.5%)</td>
<td>NR</td>
<td>0</td>
<td>6/36 (17%) at median 6.5 months (IQR, 11.6–29.3)</td>
<td>24 NR</td>
<td></td>
</tr>
<tr>
<td><strong>RFA</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sengupta (8)</td>
<td>66 HGD out of 121 HGD, LGD, IMC, indefinite dysplasia</td>
<td>4/121 (3.3%)</td>
<td>4 [2–7]</td>
<td>3 [1–12]</td>
<td>3/121 (2.5%)</td>
<td>NR</td>
<td>3/121 (2.5%)</td>
<td>30/121 (24.8%)</td>
<td>3/91 (3%) at median 8 months</td>
<td>NR</td>
<td>99.2%</td>
</tr>
<tr>
<td><strong>EMR +/- RFA</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yamashita (6)</td>
<td>14 HGD out of 28 HGD, LGD, IMC intermediate dysplasia</td>
<td>4/28 (14.3%)</td>
<td>2 [1–5]</td>
<td>3.5 [2–5]</td>
<td>2/28 (7.1%)</td>
<td>1/28 (3.6%)</td>
<td>2/11 (18.2%)</td>
<td>3/14 NR</td>
<td>NR</td>
<td>13.3 NR</td>
<td></td>
</tr>
<tr>
<td>Small (9)</td>
<td>135 HGD, 111 IMC</td>
<td>NR</td>
<td>2 [1–5] HGD, 2 [1–3] HGD, IMC, 3 [1–4] IMC, 2 [1–3] IMC</td>
<td>1/72 (1.4%)</td>
<td>1/135 (0.7%)</td>
<td>NR</td>
<td>22/135 (16.3%)</td>
<td>9/113 (8%) at median 18 months</td>
<td>37 (IQR, 19–59)</td>
<td>90.2%</td>
<td></td>
</tr>
<tr>
<td>Al Natour (17)</td>
<td>32 HGD, 28 IMC</td>
<td>0</td>
<td>4 [2–7]</td>
<td>1 EMR [1–2], 3 RFA [2–5]</td>
<td>13/60 (21.7%)</td>
<td>0</td>
<td>11/60 (18.3%)</td>
<td>1/32 (3.1%)</td>
<td>2/60 (3%) HGD</td>
<td>NR</td>
<td>NR</td>
</tr>
<tr>
<td>Oliphant (18)</td>
<td>63 HGD, 9 IMC</td>
<td>8/72 (11.1%)</td>
<td>NR</td>
<td>4 [1–11]</td>
<td>7/72 (9.7%)</td>
<td>8/63 (12.7%)</td>
<td>6/72 (8.3%)</td>
<td>NR</td>
<td>NR</td>
<td>38 (range, 12 months–7 years)</td>
<td>NR</td>
</tr>
<tr>
<td><strong>ESD</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Zhang (19)</td>
<td>45 HGD out of 102 IMC or other SCC</td>
<td>1/102 (1.0%)</td>
<td>NR</td>
<td>NR</td>
<td>28/102 (27.5%)</td>
<td>0</td>
<td>26/102 (25.5%)</td>
<td>0</td>
<td>1/45 (2%), 3/102 (3%)</td>
<td>33.6 (range, 3–81 months)</td>
<td>NR</td>
</tr>
<tr>
<td><strong>Combination of ablation techniques +/- EMR</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yasuda (20)</td>
<td>103 HGD, 80 IMC</td>
<td>3/183 (1.6%)</td>
<td>133 BE ≥5 cm</td>
<td>NR</td>
<td>NR</td>
<td>20/183 (10.9%)</td>
<td>29/183 (15.8%)</td>
<td>NR</td>
<td>20/183 (11%) at median 11.5 months</td>
<td>39 (range, 5–179 months)</td>
<td>77%</td>
</tr>
<tr>
<td>Guarner-Argente (10)</td>
<td>166 HGD, IMC and other dysplasia</td>
<td>1/166 (0.6%)</td>
<td>2 [1–5]</td>
<td>2 [1–3]</td>
<td>42/166 (25.3%)</td>
<td>3/166 (1.8%)</td>
<td>21/166 (12.7%)</td>
<td>8/166 (4.8%)</td>
<td>18/166 (11%) at median 16 months</td>
<td>39 (range, 24–62)</td>
<td>86%</td>
</tr>
<tr>
<td>Moss (21)</td>
<td>75 HGD or early adenocarcinoma</td>
<td>7/75 (9.3%)</td>
<td>3.6 [1–16]</td>
<td>1 [1–5]</td>
<td>7/75 (9.3%)</td>
<td>6/70 (8.6%)</td>
<td>6/75 (8.0%)</td>
<td>NR</td>
<td>0 at mean 31 months</td>
<td>31 (range, 3–89)</td>
<td>NR</td>
</tr>
</tbody>
</table>

Table 2 (continued)
Table 2 (continued)

<table>
<thead>
<tr>
<th>Therapy</th>
<th>N</th>
<th>Referred for surgery</th>
<th>BE length [IQR] in cm</th>
<th>Number of treatments</th>
<th>Complications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lada (22)</td>
<td>45</td>
<td>HGD, 12 IMC</td>
<td>NR</td>
<td>2/257</td>
<td>0/257</td>
</tr>
<tr>
<td>Hunt (23)</td>
<td>38</td>
<td>HGD and IMC</td>
<td>NR</td>
<td>1/257</td>
<td>1/257</td>
</tr>
<tr>
<td>Qumseya (24)</td>
<td>52</td>
<td>HGD, 64 EAC</td>
<td>NR</td>
<td>1/257</td>
<td>1/257</td>
</tr>
</tbody>
</table>

BE, Barrett’s esophagus; IQR, interquartile range; IMC, intramucosal carcinoma; NR, not recorded; LGD, low-grade dysplasia; EMR, endoscopic mucosal resection; RFA, radiofrequency ablation; SCC, squamous cell carcinoma; EAC, esophageal adenocarcinoma.

Patients (3%) went on to esophagectomy due to persistent dysplasia. Incomplete eradication of dysplasia after RFA was associated with longer length of BE [7 cm (IQR, 4–10 cm) vs. 4 cm (IQR, 2–6 cm), P=0.004]. Hiatal hernia was also associated with incomplete eradication. A hiatal hernia was present in 83% of those without complete eradication and 55% of patients with complete eradication of dysplasia, P=0.005. Despite lack of detail regarding the eradication and hernia size in that study, other studies have suggested that hiatal hernia >4 cm, and histology of HGD or adenocarcinoma after initial ablation are significantly associated with recurrence of development of adenocarcinoma after ablation (20). Additionally, in a study of 90 patients who underwent EMR with ablation, only long segment BE was an independent predictor of recurrence of neoplasia or BE, odds ratio (OR) 2.73 with a 95% CI: 1.01–7.38 (26). Treatment failures in a study of 166 patients treated with EMR and ablation occurred in 8 patients (4.8%). All patients in whom complete eradication could not be achieved had multifocal HGD at initial treatment and 7 had long segment BE (≥5 cm). The HGD progressed to cancer in three cases (10). All identified risk factors for recurrence and failure of eradication are listed in Table 3. Both the exact size of hiatal hernia and length BE where endoscopy therapy fails is yet to be defined. However, these studies suggest a hiatal hernia >4 cm and BE length ≥5 cm were less likely to achieve complete eradication of dysplasia (8,10,20,26).

Patient compliance with multiple treatments over a prolonged time period is necessary. The majority of patients need more than a single treatment for eradication of disease. In a study of 166 patients, 105 with HGD and 71 with intramucosal carcinoma, undergoing multiple modality endoscopic therapy, only 53/166 (32%) achieved complete eradication of dysplasia with a single treatment (10). In the same study, three patients had persistent HGD up to 50 months after initial endoscopic therapy (10).

There were no papers identified that evaluated outcomes of patients with poor motility, uncontrollable reflux symptoms, dysphagia, or frequent aspiration. Therefore, no statement can be made regarding applicability of endoscopic intervention for these patients.

**Esophagectomy after endotherapy**

Confirming the findings associated with failed endotherapy, a multi-institutional study found that of those referred for surgery, 73% had long segment BE, 93% had a
Figure 2 Treatment decision algorithm.

Table 3 Identified risk factors for recurrence and failure of eradication of HGD with endoscopic therapy (9,10,20,23,26)

<table>
<thead>
<tr>
<th>Factor</th>
<th>OR (95% CI) or success vs. failure %, P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (9,10)</td>
<td>1.10 (1.00–1.20), P=0.04</td>
</tr>
<tr>
<td>Multifocal dysplasia (10,23)</td>
<td>1.08 (1.01–1.15), P=0.032</td>
</tr>
<tr>
<td>Multifocal dysplasia (10,23)</td>
<td>3.22 (1.11–9.39), P=0.032</td>
</tr>
<tr>
<td>Histology of HGD or adenocarcinoma after initial ablation (20)</td>
<td>4.14 (1.489–11.519), P=0.0065</td>
</tr>
<tr>
<td>Hiatal hernia &gt;4 cm (20)</td>
<td>3.649 (1.193–11.165), P=0.0233</td>
</tr>
<tr>
<td>Long segment BE (26)</td>
<td>2.73 (1.01–7.38)</td>
</tr>
<tr>
<td>Nodular or ulcer (23)</td>
<td>39% vs. 90%, P=0.009</td>
</tr>
</tbody>
</table>

HGD, high grade dysplasia; OR, odds ratio; CI, confidence interval; BE, Barrett's esophagus.
nodule or ulcer, and 91% had multifocal disease on initial endoscopy (27). Patients in this series underwent endotherapy for a mean of 13 months (range, 4–36 months) before referral for surgery. Patients were referred for surgery due to pathologic progression of disease (53%), failure to clear disease (33%), or recurrence of HGD or IMC during surveillance after it had been cleared (13%). Strictures developed in 20% of patients during endotherapy. On final surgical pathology four patients (27%) had submucosal cancer at resection and three of these patients (20% of the total group) had positive lymph nodes (LNs). These four patients were more likely to have IMC on initial endoscopy and underwent more endotherapy sessions. This study concluded that when the endoscopist is unable to eradicate the dysplastic epithelium after three sessions of RFA, the patient has IMC on index biopsy or nodular Barrett’s, and/or the patient develops a stricture during therapy, restaging and consideration of surgery should be discussed with the patient due to the lack of published guidelines (27).

Cost effectiveness

Endoscopic treatment, including continued surveillance, is cost effective over esophagectomy. Markov modeling demonstrated a cost savings of $21.8K for a 65-year-old patient treated with EMR and RFA combination therapy compared to esophagectomy (28). However, esophagectomy was found to be more cost effective for HGD variants that carry a 30% rate per year progression to cancer, which were identified as ulcerated, nodular, and diffuse HGD in the model. Additionally, surveillance, to identify patients early in their disease, would likely result in cost savings as lower stage esophageal cancer is less costly than advanced cancer requiring multi-modality treatment. Compared with current practice, potential incremental benefit is greatest for early detection in a BE surveillance program resulting in a gain of $4,971 by shifting 20% patients presenting with stage T3 cancer to HGD or T1 (29).

Survival

The 5-year survival for patients with HGD following successful endoscopic treatment appears equivalent to surgery (Table 2). Despite lack of comparative prospective trials, the overall survival for HGD treated with endoscopic therapy and surgery are similar. The 5-, 10- and 15-year survival following esophagectomy for HGD is 94%, 82%, and 75% (30). The 5- and 8-year survival following EMR +/- ablation is 90.2% and 79.9% (9).

Role/frequency of fundoplication

Only three papers mentioned the use of a fundoplication for reflux control. In all 20 papers combined, with over 781 HGD patients, there were six Nissens preformed pre-endoscopic therapy and 13 performed following endoscopic therapy. Notably, a majority of patients who underwent a fundoplication had their endoscopic treatments performed by a surgeon, rather than a gastroenterologist. No comparison or outcomes related to the use of fundoplication was reported (6,22,23).

Discussion

The diagnosis and management of HGD is an evolving and complex problem. Although Inoue introduced the concept of EMR in 1992, the use of endoscopic treatment for HGD and IMC was not popularized for another decade following the results of a study by Ell and colleagues where they showed successful endoscopic treatment with low morbidity and mortality (1,31). Endoscopic treatments have continued to evolve since being endorsed in 2009, and new technologies and techniques are continuing to be developed.

Although endoscopic treatments are often successful and allow for esophageal preservation, a subset of patients will require multiple treatments and/or have a high risk of disease recurrence. Certain patients, yet to be clearly defined, should be considered for esophagectomy as first-line treatment. In patients who have failed endoscopic therapy, esophagectomy should be considered as salvage treatment.

An esophagectomy is a complex operation with significant morbidity and mortality. Modern outcomes have decreased the incidence of mortality, which is now under 5% (32,33). There is still a major complication rate of 33%. The most common major complications include
pneumonia, re-intubation, and anastomotic leak (33). 
Endoscopic therapy can be performed with minimal risks, 
although complications still exist. Serious adverse events 
following endoscopic therapy are reported in approximately 
3% of patients with a stricture rate ranging from 3% to 
26% following a combination of treatments. Additionally, 
stricture rate increases with the percentage of the resected 
circumference and the number of resected specimens (34).

Nonetheless, there are several issues with endoscopic 
treatment of HGD and IMC. A significant issue is 
whether there is appropriate expertise of the pathologist 
to differentiate HGD from IMC. One study found that 
community pathologists failed to identify invasive cancer 
in an HGD specimen 30% of the time (9). Additionally, 
when ER is performed there can be mis-interpretation 
of the specimen. In a multi-institutional study of 25 ER 
specimens there was an alarmingly high rate of discordance 
(48%) between study pathologists and original pathologic 
assessment (35). Pathologic diagnosis is what drives 
the decision algorithm. Therefore, understanding the 
institution-specific limitations of pathology programs will 
aid in making a successful endoscopic surveillance and 
treatment plan for patients with HGD.

The difficulties among expert pathologist to distinguish 
HGD from IMC and submucosal cancer has resulted in 
much of the literature combining high grade dysplasia and 
early esophageal cancer into one category (36). However, 
these are two intrinsically distinct disease processes. IMC 
is increasingly being treated with the same algorithms as 
HGD, receiving multiple endoscopic therapies prior to 
being considered for resection. However, IMC still carries 
a 3% risk of LN involvement (37,38). If IMC progresses 
to submucosal cancer during treatment, the risk of LN 
involvement goes up to 20%. Patients that have LN 
involvement have a 5-year survival rate of 45–67%—
dramatically reduced compared to 90–95% 5-year survival 
in patients with early esophageal cancer (39,40). There are 
well defined histologic characteristics that are associated 
with LN involvement: poor differentiation, lympho- 
vascular invasion, and multifocal HGD (41). When these 
features are seen on ER specimens, patients should be 
strongly considered for esophagectomy. While there is great 
evidence that low risk IMC can be cured by endoscopic 
therapy, future studies should separate these two disease 
processes to better define endoscopic outcomes for HGD 
and IMC individually.

Patients eligible for surgery who present with long 
segment BE (≥5 cm), multifocal dysplastic lesions, severe 
reflux symptoms, a large hiatal hernia, or dysphagia 
comprise a challenging group with regard to the appropriate 
treatment, either surgical or endoscopic. Other review 
articles have addressed the common perception that these 
patients would likely be better treated with esophagectomy. 
Specifically, long segment BE, large tumors, visible 
ulceration, and the presence of a hiatal hernia or prior 
fundoplication should warrant consideration of surgical 
over endoscopic treatment (42).

The majority of studies evaluating the effect of 
endoscopic treatments for HGD do not mention surgery. 
They continue to re-treat recurrences endoscopically 
and do not discuss timing of referral to surgery. Many of 
these studies exclude patients who progressed to cancer 
which, presumably is the time patients are referred for 
surgical resection. This gap in the literature begs the 
question: when is the time to stop endoscopic management 
and consider surgery for HGD? Hunt and colleagues 
suggest that when the endoscopist is unable to eradicate 
the dysplastic epithelium after three sessions of RFA, the 
patient has IMC on index biopsy or nodular Barrett’s, and/ 
or the patient develops a stricture during therapy, restaging 
and consideration of surgery should be discussed with 
the patient due to the lack of published guidelines (27). 
These guidelines seem reasonable. However, there are no 
papers that have shown the number of treatments or that 
the presence of a stricture is associated with treatment 
failure. If patients understand the potential consequences 
of endoscopic therapy, then the number of treatments 
performed may be of no significance to their long-
term outcomes. Additionally, strictures from endoscopic 
treatments may be superficial and treatable with dilation. In 
a study of patients undergoing photodynamic therapy (PDT) 
94% of those that had developed post-PDT strictures 
were structure-free at completion of the 2-year follow-
up following multiple dilations (43). Due to the repeat 
nature of endoscopic therapy, patients who are not likely 
to be compliant with repeated endoscopy and surveillance 
should be considered for more definitive therapy with 
esophagectomy. This review identified multiple factors that 
were associated with treatment failure; nodules or ulcers, 
multifocal dysplasia, large hiatal hernias, long segment BE 
and persistent HGD after initial treatment (9,10,20,31).

Patients should additionally be counseled about the 
logistics of lifetime surveillance before undergoing 
endoscopic therapy for HGD. This is extremely necessary 
due to reports of recurrent dysplasia following endoscopic 
treatment out to 85 months (26). In a study that followed
patients for a median of 6.8 years there was a 40% risk of recurrence of intestinal metaplasia and HGD following complete eradication of intestinal metaplasia (44). Of more concern, there is no decrease in the risk of recurrence over time (45). The ACG recommends surveillance after treatment of BE with HGD every 3 months for the first year, every 6 months for the second year and annually thereafter (25).

The population that still needs to be addressed are those patients diagnosed with HGD with concomitant severe reflux, motility disorders, or dysphagia. This group of patients are likely to have esophageal disease that may not respond as well to endoscopic treatment and is more appropriate for surgical resection, however, there are no studies that have specifically addressed this issue.

Another unanswered question is which endoscopic treatment option results in the best long-term outcomes with the lowest complication profile once HGD is identified. From this review, the combination therapies have the most success in regards to recurrence and survival with lower or equivalent stricture rates. Using just one therapy option and failing to completely eradicate dysplasia and intestinal metaplasia resulted in earlier recurrences. There continues to be advances in the options for endoscopic therapy and the ideal treatment may still be undefined. Regardless of the technique, it is clear that the key to success is complete eradication of intestinal metaplasia. Without complete eradication, there is a higher risk of recurrence of the BE, HGD, and IMC (46,47).

Additionally, beyond the scope of this review, but there is an increase in the role of fundoplication and endoscopic therapy. Patients in this review who underwent a fundoplication following endoscopic treatments are more likely to have their endoscopic treatment performed by a surgeon rather than a gastroenterologist. The ACG recommends that antireflux surgery should not be pursued in patients with BE as an antineoplastic measure. However, fundoplication should be considered in those with incomplete control of reflux symptoms on optimized medical therapy (25).

The main limitation of this study is it is a review of multiple studies with different selection criteria. Additionally, there are new treatment options becoming available as endoscopic management becomes more conventional. Some of these options may improve the outcomes for endoscopic therapy for HGD and eventually make surgery for HGD obsolete. Until this can be proven with lower recurrence rates there still remains a role for esophagectomy in this disease. Reviewing the differences in effectiveness of various endoscopic therapies outside the scope of this review. It was difficult to truly compare these patients as many of the endoscopic treatment studies excluded from their final analysis patients who needed surgery or had an incomplete ER. Another important limitation is that much of the literature combines HGD and IMC cancer in to one group, although we attempted to separate these as best as possible to examine only patients with HGD.

In conclusion, most patients are candidates for endoscopic intervention for HGD. Prior to beginning endoscopic therapy, all patients should be discussed in a multi-disciplinary setting. Combination therapy with varying ablation techniques and ER offers the best short-term outcomes, but carries a higher risk of recurrence, and these patients require long term surveillance. Patients with nodules or ulcers, multifocal dysplasia, large hiatal hernias, long segment BE, or persistent HGD after initial treatment should be counseled on their increased risk of recurrence and failure. These patients should be presented the risks and benefits of esophagectomy. Further, patients should understand the risk of stricture and disease progression as well as the need for lifelong surveillance and treatment prior to undergoing endoscopic therapy over esophagectomy for HGD.

Acknowledgments
None.

Footnote
Conflicts of Interest: CW Towe reports that he is a consultant for Zimmer Biomet, SigMedical, Atricure and Medtronic, but that these relationships have not affected this manuscript or the accuracy of the data analysis. The other authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

References


doi: 10.21037/aoe.2020.01.01

© Annals of Esophagus. All rights reserved.

Ann Esophagus 2020;3:5 | http://dx.doi.org/10.21037/aoe.2020.01.01